COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00985868
Recruitment Status : Completed
First Posted : September 29, 2009
Last Update Posted : November 29, 2019
Information provided by (Responsible Party):
Cancer Research UK

Brief Summary:

RATIONALE: AT9283 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of AT9283 in children and adolescents with relapsed and refractory solid tumors.

Condition or disease Intervention/treatment Phase
Unspecified Childhood Solid Tumor, Protocol Specific Drug: multikinase inhibitor AT9283 Other: enzyme-linked immunosorbent assay Other: immunohistochemistry staining method Other: laboratory biomarker analysis Other: pharmacological study Phase 1

Detailed Description:



  • To evaluate the safety and tolerability of Aurora kinase inhibitor AT9283 by characterizing the dose-limiting toxicities in children and adolescents with relapsed and refractory solid tumors.
  • To determine the maximum-tolerated dose of this regimen in these patients.


  • To determine the pharmacokinetic parameters of this regimen in these patients.
  • To demonstrate the pharmacodynamic (PD) activity of this regimen in these patients by studying its effects in surrogate tissue.
  • To assess preliminary evidence of activity of this regimen by using appropriate objective tumor measurements in these patients.


  • To demonstrate the PD activity of this regimen in these patients by studying its effects in both surrogate and tumor tissue (skin punch, bone marrow, and tumor biopsies).

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive Aurora kinase inhibitor AT9283 IV over 72 hours on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.If a patient is benefiting from treatment with AT9283 (i.e. has stable or responding disease as measured by RECIST) and the benefit risk balance is considered acceptable then further treatment may be given.

Blood and skin tissue samples are collected at baseline and periodically during treatment for pharmacokinetic studies and pharmacodynamic and biomarker (M30, M65, pHH53, p53, PCNA and Ki67) analysis by IHC and ELISA assays.

After completion of study therapy, patients are followed up periodically.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A CCLG/Cancer Research UK Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) Given for 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents With Relapsed and Refractory Solid Tumors
Study Start Date : September 2009
Actual Primary Completion Date : January 25, 2016
Actual Study Completion Date : November 20, 2019

Primary Outcome Measures :
  1. Dose-limiting toxicities
  2. Maximum-tolerated dose

Secondary Outcome Measures :
  1. Pharmacokinetic parameters and the correlation between them and toxicity and/or efficacy
  2. The magnitude and duration of biomarkers (M30 and M65 ELISA) change after AT9283 administration
  3. Objective tumor response according to RECIST criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed solid tumor meeting 1 of the following criteria:

    • Refractory to conventional treatment
    • Disease for which no conventional therapy exists
  • Patients with CNS tumors must be on a stable or decreasing dose of dexamethasone for ≥ 1 week before study entry


  • WHO performance status (PS) 0-2 OR Lansky Play PS 70-100% (> 50% is acceptable if it is due to a stable neurological deficit or CNS tumor)
  • Life expectancy ≥ 12 weeks
  • ANC ≥ 1,000/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9.0 g/dL
  • Serum bilirubin < 1.5 times upper limit of normal (ULN)
  • Creatinine kinase normal
  • ALT or AST < 2.5 times ULN (≤ 5 times ULN if due to tumor)
  • Creatinine clearance/EDTA-measured GFR ≥ 60 mL/min
  • Sufficient blood volume to undergo the blood-sampling regimen specified by the protocol that, in the opinion of the investigator, will not jeopardize patient's safety
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use 2 methods of effective contraception 4 weeks before, during, and for 6 months after completion of study therapy
  • Not at high medical risk because of non-malignant systemic disease, including active uncontrolled infection
  • Not known to be serologically positive for hepatitis B or C or HIV
  • Fractional shortening of > 29% on echocardiogram
  • LVEF ≥ 50%
  • No history of allergy or auto-immune disease
  • No congenital heart disease
  • No other condition that, in the investigator's opinion, would not make the patient a good candidate for the clinical trial


  • See Disease Characteristics
  • Recovered from prior therapy
  • More than 4 weeks since prior radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy, or chemotherapy (6 weeks for investigational medicinal products, 2 weeks for vincristine)
  • More than 3 months since prior autologous stem cell transplantation
  • No prior allogenic bone marrow transplantation
  • No prior extensive radiotherapy to > 25% of bone marrow
  • No prior Aurora kinase inhibitor
  • No prior major thoracic or abdominal surgery from which the patient has not yet recovered
  • No prior or concurrent participation in another interventional clinical trial

    • Participation in an observational study allowed
  • No other concurrent anticancer therapy or investigational drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00985868

Layout table for location information
United Kingdom
Birmingham Children's Hospital
Birmingham, England, United Kingdom, B4 6NH
Leeds General Infirmary
Leeds, England, United Kingdom, LS9 7TF
Royal Manchester Children's Hospital
Manchester, England, United Kingdom, M27 4HA
Great North Children's Hospital, Royal Victoria Infirmary
Newcastle-Upon-Tyne, England, United Kingdom, NE1 4LP
Royal Marsden - Surrey
Sutton, England, United Kingdom, SM2 5PT
Sponsors and Collaborators
Cancer Research UK
Layout table for investigator information
Principal Investigator: Darren Hargrave, MD Great Ormond Street Hospital for Children NHS Foundation Trust
Layout table for additonal information
Responsible Party: Cancer Research UK Identifier: NCT00985868    
Other Study ID Numbers: CDR0000653387
First Posted: September 29, 2009    Key Record Dates
Last Update Posted: November 29, 2019
Last Verified: November 2019
Keywords provided by Cancer Research UK:
unspecified childhood solid tumor, protocol specific
Additional relevant MeSH terms:
Layout table for MeSH terms